院外心脏骤停患者入院后低温治疗中血管内冷却与体表冷却的比较:TTM2试验的事后分析
该研究为TTM2试验的事后分析,纳入随机分配至低温治疗的院外心脏骤停患者930例,其中876例使用冷却装置并纳入分析,27.3%使用血管内冷却装置(IC),72.7%使用体表冷却装置(SFC)。主要结局为冷却性能:IC组4小时内达到目标温度<33.5°C的比例为69.6%,高于SFC组的49.2%(p<0.001);冷却期间温度偏离范围为17.2% vs 39.6%(p<0.001),低温治疗后发热为0% vs 6.3%(p<0.001)。探索性IPTW分析显示,6个月生存率IC组55.2% vs SFC组50.2%(OR 1.22,95%CI 0.89-1.68),6个月良好功能结局(mRS 0-3)IC组51.1% vs SFC组44.9%(OR 1.28,95%CI 0.93-1.77)。结论认为血管内冷却与更好的冷却性能相关。
要点
- 在TTM2试验随机接受低温治疗的院外心脏骤停患者中,血管内冷却组4小时内达到目标温度<33.5°C的比例为69.6%,高于体表冷却组的49.2%(p<0.001)。
- 血管内冷却组冷却期间温度偏离范围为17.2%,低于体表冷却组的39.6%(p<0.001);低温治疗后发热为0%,低于体表冷却组的6.3%(p<0.001)。
- 探索性IPTW分析中,6个月生存率血管内冷却组55.2% vs 体表冷却组50.2%(OR 1.22,95%CI 0.89-1.68),未达统计学显著。
- 6个月良好功能结局(mRS 0-3)血管内冷却组51.1% vs 体表冷却组44.9%(OR 1.28,95%CI 0.93-1.77),未达统计学显著。
- 作者结论认为,在TTM2研究中随机接受低温治疗的院外心脏骤停患者中,血管内冷却相比体表冷却与更好的冷却性能相关。
适用人群与场景
- TTM2试验(NCT02908308)中随机分配至低温治疗的院外心脏骤停患者,最终876例使用冷却装置者纳入本事后分析。
- 患者为入院后接受低温治疗者;原文未报告其他纳入或排除标准。
诊断标准与关键阈值
- 目标温度管理目标为33°C;冷却性能主要定义为4小时内达到目标温度<33.5°C的患者比例。
处置流程与药物剂量
- 低温治疗使用血管内冷却装置或体表冷却装置,具体设备型号、操作方案及复温速率原文未报告。
研究设计与关键结果
- 研究类型:TTM2试验的事后分析;纳入随机分配至低温治疗的院外心脏骤停患者930例,其中876例使用冷却装置并纳入分析(血管内冷却27.3%,体表冷却72.7%)。
- 主要结局:4小时内达到目标温度<33.5°C的比例血管内冷却组69.6% vs 体表冷却组49.2%(p<0.001)。
- 冷却期间温度偏离范围血管内冷却组17.2% vs 体表冷却组39.6%(p<0.001);低温治疗后发热血管内冷却组0% vs 体表冷却组6.3%(p<0.001)。
- 探索性IPTW分析:6个月生存率血管内冷却组55.2% vs 体表冷却组50.2%(OR 1.22,95%CI 0.89-1.68);6个月良好功能结局(mRS 0-3)血管内冷却组51.1% vs 体表冷却组44.9%(OR 1.28,95%CI 0.93-1.77)。
证据类型、等级与局限
- 证据类型:TTM2随机对照试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于院外心脏骤停后入院接受33°C低温治疗的患者,选用血管内冷却装置可能比体表冷却装置更快达到目标温度并减少温度偏离及低温治疗后发热(作者结论)。
- 血管内冷却与体表冷却在6个月生存率(OR 1.22,95%CI 0.89-1.68)和良好功能结局(OR 1.28,95%CI 0.93-1.77)上未达统计学显著差异,不能据此推荐某一种装置改善远期结局。
指南或共识出处
- TTM2试验(NCT02908308)的事后分析,发表于Intensive Care Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To compare the performance of targeted temperature management (TTM) at 33 °C using intravascular (IC) vs. surface-cooling (SFC) devices after out-of-hospital cardiac arrest (OHCA).
METHODS: A post hoc analysis including OHCA patients randomized to hypothermia in the TTM2-trial (NCT02908308) comparing hypothermia with normothermia. The main outcome was cooling performance, defined as the proportion of patients reaching target temperature < 33.5 °C within 4 h, time outside temperature ranges during maintenance, rewarming rate and post-TTM fever. Exploratory outcomes included survival and good functional outcome, defined as modified Rankin Scale (mRS) scores of 0-3 at 6 months, analyzed using Inverse Probability Treatment Weighting (IPTW).
RESULTS: Among 930 patients randomized to hypothermia, 876 were treated with a cooling device and included in this study. Of those, 27.3% received IC devices, while 72.7% received SFC devices. The proportion reaching target temperature within 4 h was higher with IC (IC: 69.6% vs. SFC: 49.2%; p < 0.001). Temperature outside ranges during the cooling period and post-TTM fever were lower with IC compared to SFC (17.2% vs. 39.6%; p < 0.001 and 0% vs. 6.3%; p < 0.001, respectively). In the exploratory IPTW analysis, 6-month survival rates were 55.2% in the IC group and 50.2% in the SFC group (OR 1.22, 95% CI 0.89-1.68) and survival with good functional outcome at 6 months was 51.1% patients in the IC group and 44.9% in the SFC (OR 1.28, 95% CI 0.93-1.77).
CONCLUSIONS: Among OHCA patients randomized to hypothermia in the TTM2 study, intravascular cooling, compared with surface cooling, was associated with better cooling performance.
参考来源
- Awad A, Jonsson M, Holgersson J, et al. Intravascular vs. surface cooling in out-of-hospital cardiac arrest patients receiving hypothermia after hospital arrival: a post hoc analysis of the TTM2 trial. Intensive Care Med. 2025. PMID: 40293464. doi:10.1007/s00134-025-07883-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。